use of the new antioxidant mexidole for intensive care for ischemic attacks

The study was conducted in 60 patients with acute ischemic attack. Mexidole included into a complex of intensive care in patients with stroke promoted the abolishment of local disseminated intravascular coagulation and prevented secondary cerebral lesion and the generalization of a systemic inflammatory reaction. The rate of a reduction in the blood levels of soluble fibrin-monomer complexes and fibrinogen was higher than that in mexidole-untreated patients. By day 7, the levels of soluble fibrin-monomer complexes and fibrinogen in survivors decreased on average to 18.0±2.7 mg% and to 2—4 g/l, respectively. Mexidole optimizes the parameters of cerebral blood flow, improves venous outflow from the cranial cavity, and may be recommended for its inclusion into the intensive treatment regimen in patients with cere-brovascular diseases.